Blueprint Net Income from 2010 to 2024
| BPMC Stock | USD 88.90 0.52 0.59% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -133.7 M | Current Value -110.9 M | Quarterly Volatility 126.9 M |
Check Blueprint Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Blueprint main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.2 M, Interest Expense of 54.2 M or Selling General Administrative of 293.8 M, as well as many exotic indicators such as Price To Sales Ratio of 21.28, Dividend Yield of 0.001 or PTB Ratio of 44.91. Blueprint financial statements analysis is a perfect complement when working with Blueprint Medicines Valuation or Volatility modules.
Blueprint | Net Income |
Latest Blueprint Medicines' Net Income Growth Pattern
Below is the plot of the Net Income of Blueprint Medicines Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Blueprint Medicines Corp financial statement analysis. It represents the amount of money remaining after all of Blueprint Medicines Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Blueprint Medicines' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Blueprint Medicines' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (506.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Blueprint Net Income Regression Statistics
| Arithmetic Mean | (189,266,653) | |
| Geometric Mean | 116,066,417 | |
| Coefficient Of Variation | (139.31) | |
| Mean Deviation | 215,995,451 | |
| Median | (72,495,000) | |
| Standard Deviation | 263,664,563 | |
| Sample Variance | 69519T | |
| Range | 958M | |
| R-Value | (0.66) | |
| Mean Square Error | 41801.6T | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | (39,181,152) | |
| Total Sum of Squares | 973266T |
Blueprint Net Income History
Other Fundumenentals of Blueprint Medicines Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Blueprint Medicines Net Income component correlations
About Blueprint Medicines Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Blueprint Medicines income statement, its balance sheet, and the statement of cash flows. Blueprint Medicines investors use historical funamental indicators, such as Blueprint Medicines's Net Income, to determine how well the company is positioned to perform in the future. Although Blueprint Medicines investors may use each financial statement separately, they are all related. The changes in Blueprint Medicines's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Blueprint Medicines's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Blueprint Medicines Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Blueprint Medicines. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -507 M | -481.6 M | |
| Net Loss | -554.7 M | -527 M | |
| Net Loss | -501.8 M | -476.7 M | |
| Net Loss | (8.37) | (8.79) | |
| Net Income Per E B T | 1.00 | 0.79 |
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving against Blueprint Stock
| 0.52 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Blueprint Medicines Correlation against competitors. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.